Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 3 - You Need To See This

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Amgen Earnings Preview: What to Expect

Amgen will release its third-quarter earnings this month, and analysts anticipate a single-digit bottom-line growth.

Barchart

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Amgen Stock Outperforming the Nasdaq?

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.

Barchart

AMGN Bullish Diagonal Trade Targets a Price of $350 by October 18th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

What You Need to Know Ahead of Amgen's Earnings Release

Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

StockNews.com

Is Amgen Stock Outperforming the S&P 500?

Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.

Barchart

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Barchart

3 Biotech Stocks With Potential Breakthroughs Emerging

The biotech industry's future is promising, driven by advanced technologies like AI and VR, the rising popularity of personalized treatments, and increased R&D spending. Let's analyze the investment prospects of biotech stocks Amgen (AMGN), United Therapeutics (UTHR), and Gilead Sciences (GILD) as potential breakthroughs emerge. Read more.

StockNews.com

What Are Wall Street Analysts' Target Price for Amgen Stock?

Amgen has outperformed the broader market and many of its peers over the past year, but Wall Street analysts believe it has limited upside left.

Barchart

3 Biotech Stocks Poised for May Surges

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

AMGN Earnings Spotlight: Analyzing Potential Gains

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…

StockNews.com

Analyzing 3 Biotech Stocks for 2024 Gain Potential

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

StockNews.com

3 Biotech Stocks Signaling Buy Opportunities

The biotech industry is well-positioned to generate returns amid breakthrough developments and the growing prevalence of chronic diseases. Given the solid long-term prospects of the industry, fundamentally sound biotech stocks Entrada Therapeutics (TRDA), Alkermes (ALKS) and Amgen (AMGN) could be ideal buys for steady gains. Read on.

StockNews.com

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

StockNews.com

Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

StockNews.com

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally robust stocks like Incyte Corp. (INCY), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) could contribute to the health and wealth of your portfolios. Read more….

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.